BPTH BIO-PATH HOLDINGS, INC.

OTC Pharmaceutical Preparations DE CIK: 0001133818
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

Bio-Path Holdings is in critical financial distress with zero revenue, negative stockholders' equity of -$8.0M, and severe liquidity constraints (0.08x current ratio). The company is burning cash at -$1.6M annually with no operating income while carrying $8.7M in liabilities against only $690K in assets, indicating imminent solvency risk.

Strengths

  • + No long-term debt obligations reducing refinancing risk
  • + Minimal capital expenditure requirements suggesting asset-light operations
  • + EPS improvement of 87.7% YoY indicates reduced dilution rate

Risks

  • ! Negative stockholders' equity of -$8.0M indicates balance sheet insolvency
  • ! Zero revenue generation with -$8.3M operating loss signals complete operational failure
  • ! Critical liquidity crisis with $0 cash and 0.08x current ratio threatening going concern status
  • ! Negative free cash flow of -$1.6M draining remaining capital resources
  • ! Total liabilities ($8.7M) exceed total assets ($690K) by 12.6x indicating balance sheet collapse

Key Metrics to Watch

Financial Metrics

Revenue
0.0
Net Income
-8.4M
EPS (Diluted)
$-1.07
Free Cash Flow
-1.6M
Total Assets
690.0K
Cash
0.0

Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -1,221.0%
FCF Margin N/A

Balance Sheet & Liquidity

Current Ratio
0.08x
Quick Ratio
0.08x
Debt/Equity
N/A
Debt/Assets
1,260.0%
Interest Coverage
-207.28x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-03-21T10:42:10.293577 | Data as of: 2025-09-30 | Powered by Claude AI